The growth hormone deficiency treatment landscape has been stuck in a rut for decades—daily injections that disrupt routines and test the limits of patient tolerance, especially for kids who'd rather be doing anything else. SKYTROFA crashes onto the scene as a long-acting alternative that actually gets what patients need: less hassle, same results. By slashing injection frequency without...